Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - hif-2
1
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic
Abstract: The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target
HIF-2
a in cancer. Elevated HIF-2a is associated with clear cell kidney cancer characterized by mutation of the...
Published: 4/8/2024
|
Inventor(s):
William Linehan
,
Tracey Rouault
,
James Mitchell
,
Murali Cherukuri
Keywords(s):
clear cell
,
HIF-2
,
kidney cancer
,
NITROXIDE
,
Tempol
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
TherapeuticArea > Oncology
,
Application > Therapeutics